Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Yuzhong Chen,Shaodi Wen,Jingwei Xia,Xiaoyue Du,Yuan Wu,Banzhou Pan,Wei Zhu,Bo Shen

DOI: https://doi.org/10.3389/fimmu.2021.713268

IF: 7.3

2021-06-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.672271.].

immunology

What problem does this paper attempt to address?

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Youlong Wang,Qi Huang,Guanqing Zhong,Jun Lv,Qinzhi Guo,Yifei Ma,Xinjia Wang,Jiling Zeng

DOI: https://doi.org/10.3389/fonc.2024.1376408

IF: 4.7

2024-02-29

Frontiers in Oncology

Abstract:This article is a correction to: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

oncology
Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Yin Yang,Jianyang Wang,Wenqing Wang,Tao Zhang,Jingjing Zhao,Yu Wang,Yexiong Li,Luhua Wang,Nan Bi

DOI: https://doi.org/10.3389/fonc.2022.1007862

IF: 4.7

2022-08-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.810580.].

oncology
Corrigendum: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

Dongshan Chen,Chen Zhang,Yuanwei Zang,Wei Wang,Jiandong Zhang

DOI: https://doi.org/10.3389/fgene.2024.1440802

IF: 3.7

2024-06-27

Frontiers in Genetics

Abstract:This article is a correction to: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

genetics & heredity
Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Yueyun Pan,Yinda Yu,Xiaojian Wang,Ting Zhang

DOI: https://doi.org/10.3389/fimmu.2021.775758

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2020.583084.].
Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity

Hao Zheng,Wen-juan Zheng,Zhen-guang Wang,Yuan-ping Tao,Zhi-ping Huang,Le Yang,Liu Ouyang,Zhi-qing Duan,Yi-nuo Zhang,Bo-ning Chen,Dai-min Xiang,Gang Jin,Lu Fang,Fan Zhou,Bo Liang

DOI: https://doi.org/10.3389/fimmu.2022.1093403

IF: 7.3

2022-12-08

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.845193.].

immunology
Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients

Chao Xia,Wei Huang,Yun-Liang Chen,Hai-Bin Fu,Ming Tang,Tao-Lan Zhang,Jing Li,Guo-Hua Lv,Yi-Guo Yan,Zhi-Hua Ouyang,Nvzhao Yao,Cheng Wang,Ming-Xiang Zou

DOI: https://doi.org/10.3389/fimmu.2023.1194064

IF: 7.3

2023-04-14

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.797407.].

immunology
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Qitong Chen,Dengjie Ouyang,Munawar Anwar,Ning Xie,Shouman Wang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boni Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi,Quchang Ouyang

DOI: https://doi.org/10.3389/fonc.2021.661128

IF: 4.7

2021-03-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00811.].

oncology
Corrigendum: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma

Yicong Yao,Yi Wang,Denglong Wu,Baoying Hu

DOI: https://doi.org/10.3389/fonc.2021.731942

IF: 4.7

2021-07-21

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.666418.].

oncology
Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Yongrong Lei,Xishu Wang,Heng Sun,Yuna Fu,Yichen Tian,Ludi Yang,Jianhua Wang,Feng Xia

DOI: https://doi.org/10.3389/fonc.2024.1438731

2024-07-10

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.601668.].
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

Daling Dong,Shixin Zhang,Bin Jiang,Wei Wei,Chao Wang,Qian Yang,Tingzhi Yan,Min Chen,Liken Zheng,Weikang Shao,Gang Xiong

DOI: https://doi.org/10.3389/fonc.2023.1275851

IF: 4.7

2023-08-25

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1222716.].

oncology
Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis

Mingchuang Zhu,Qingpeng Zeng,Tao Fan,Yuanyuan Lei,Feng Wang,Sufei Zheng,Xinfeng Wang,Hui Zeng,Fengwei Tan,Nan Sun,Qi Xue,Jie He

DOI: https://doi.org/10.3389/fimmu.2022.909105

IF: 7.3

2022-05-04

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.783495.].

immunology
Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Thomas Morgan Hulen,Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J W Peeters,Marco Donia,Mads Hald Andersen,Sine Reker Hadrup,Inge Marie Svane,Özcan Met

DOI: https://doi.org/10.3389/fimmu.2024.1462081

2024-07-18

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Yunfu Deng,Guangzhi Ma,Karin A. Vallega,Dongsheng Wang,Mingliang Wang,Changwei Wang,Shaomeng Wang,Suresh S. Ramalingam,Shi-Yong Sun

DOI: https://doi.org/10.1038/s41417-022-00479-w

IF: 5.854

2022-05-10

Cancer Gene Therapy

Abstract:Cancer Gene Therapy, Published online: 10 May 2022; doi:10.1038/s41417-022-00479-w Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Corrigendum: T lymphocyte cell: A pivotal player in lung cancer

Yanan Wu,Meng Yuan,Chenlin Wang,Yanfei Chen,Yan Zhang,Jiandong Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1166352

IF: 7.3

2023-02-21

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1102778.].

immunology
Corrigendum: Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study

Qi Zheng,Hanzhou Wang,Wei Hou,Ying Zhang

DOI: https://doi.org/10.3389/fcvm.2021.828274

IF: 3.6

2022-01-06

Frontiers in Cardiovascular Medicine

Abstract:[This corrects the article DOI: 10.3389/fcvm.2021.755191.].

cardiac & cardiovascular systems
Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Sha-Sha Wang,Fang Wang,Zhen Zeng,Fang Gao,Huan-Huan Liu,Hui-Na Wang,Yi Hu,Hai-Feng Qin

DOI: https://doi.org/10.3389/fonc.2022.1113289

IF: 4.7

2022-12-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.929763.].

oncology
Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis

Xu-Sheng Liu,Lu-Meng Zhou,Ling-Ling Yuan,Yan Gao,Xue-Yan Kui,Xiao-Yu Liu,Zhi-Jun Pei

DOI: https://doi.org/10.3389/fimmu.2021.751004

IF: 7.3

2021-08-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.724741.].

immunology

Corrigendum: Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Corrigendum: Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell–mediated antitumor activity

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Corrigendum: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma

Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum: T lymphocyte cell: A pivotal player in lung cancer

Corrigendum: Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis